Scarica l'app Stockscreener
57.29
2.55%
-1.50
Dopo l'orario di chiusura:
56.45
-0.84
-1.47%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché HALO Giù?
Forum
Previsione
Precedente Chiudi:
$58.79
Aprire:
$58.74
Volume 24 ore:
1.27M
Relative Volume:
0.92
Capitalizzazione di mercato:
$7.58B
Reddito:
$947.36M
Utile/perdita netta:
$392.47M
Rapporto P/E:
18.97
EPS:
3.02
Flusso di cassa netto:
$392.71M
1 W Prestazione:
-6.68%
1M Prestazione:
-12.08%
6M Prestazione:
+10.66%
1 anno Prestazione:
+48.27%
Intervallo 1D:
$56.47
$58.99
Intervallo di 1 settimana:
$56.47
$62.14
Portata 52W:
$37.97
$66.00
Halozyme Therapeutics Inc Stock (HALO) Company Profile
Nome
Halozyme Therapeutics Inc
Settore
Industria
Telefono
(858) 794-8889
Indirizzo
12390 EL CAMINO REAL, SAN DIEGO, CA
Confronta HALO con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
HALO
Halozyme Therapeutics Inc
|
57.29 | 7.58B | 947.36M | 392.47M | 392.71M | 3.02 |
|
VRTX
Vertex Pharmaceuticals Inc
|
477.52 | 127.47B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
561.49 | 62.43B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
595.70 | 37.03B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
232.75 | 31.06B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
229.22 | 26.16B | 3.81B | -644.79M | -669.77M | -6.24 |
Halozyme Therapeutics Inc Stock (HALO) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2024-10-07 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| 2024-09-19 | Downgrade | JP Morgan | Overweight → Neutral |
| 2024-06-07 | Downgrade | Piper Sandler | Overweight → Neutral |
| 2024-02-29 | Iniziato | TD Cowen | Outperform |
| 2023-07-24 | Downgrade | Goldman | Buy → Neutral |
| 2023-07-24 | Iniziato | H.C. Wainwright | Buy |
| 2023-05-10 | Aggiornamento | Piper Sandler | Neutral → Overweight |
| 2023-03-27 | Ripresa | Berenberg | Buy |
| 2023-03-16 | Downgrade | SVB Securities | Outperform → Market Perform |
| 2022-12-21 | Ripresa | Morgan Stanley | Overweight |
| 2022-11-28 | Iniziato | Wells Fargo | Overweight |
| 2022-09-09 | Iniziato | Morgan Stanley | Overweight |
| 2022-05-23 | Iniziato | SVB Leerink | Outperform |
| 2021-06-14 | Iniziato | Evercore ISI | Outperform |
| 2021-05-17 | Iniziato | SVB Leerink | Outperform |
| 2021-05-11 | Downgrade | Piper Sandler | Overweight → Neutral |
| 2021-01-21 | Reiterato | The Benchmark Company | Buy |
| 2020-12-17 | Iniziato | Berenberg | Buy |
| 2020-09-14 | Ripresa | JP Morgan | Overweight |
| 2020-07-01 | Iniziato | The Benchmark Company | Buy |
| 2020-02-05 | Aggiornamento | Piper Sandler | Neutral → Overweight |
| 2020-01-09 | Aggiornamento | BMO Capital Markets | Market Perform → Outperform |
| 2020-01-08 | Iniziato | Goldman | Buy |
| 2019-11-05 | Aggiornamento | Barclays | Underweight → Equal Weight |
| 2018-10-19 | Ripresa | Piper Jaffray | Neutral |
| 2018-05-11 | Downgrade | Barclays | Equal Weight → Underweight |
| 2018-01-24 | Iniziato | Goldman | Neutral |
| 2017-10-16 | Reiterato | Piper Jaffray | Overweight |
| 2017-01-06 | Downgrade | Citigroup | Buy → Neutral |
| 2016-11-03 | Iniziato | Deutsche Bank | Buy |
| 2015-12-04 | Iniziato | Wells Fargo | Outperform |
| 2015-11-18 | Iniziato | Citigroup | Buy |
| 2015-09-22 | Iniziato | Barclays | Overweight |
| 2015-06-22 | Reiterato | JP Morgan | Overweight |
| 2015-03-03 | Reiterato | UBS | Buy |
| 2015-02-18 | Reiterato | MLV & Co | Buy |
| 2015-01-08 | Reiterato | MLV & Co | Buy |
Mostra tutto
Halozyme Therapeutics Inc Borsa (HALO) Ultime notizie
Halozyme Therapeutics (NASDAQ:HALO) Has A Rock Solid Balance Sheet - simplywall.st
If EPS Growth Is Important To You, Halozyme Therapeutics (NASDAQ:HALO) Presents An Opportunity - Yahoo Finance
Biotech Stock Bounces From Support, Shows Relative Strength Amid Volatile Market - MSN
Halozyme Announces FDA Approval of argenx's VYVGART® Hytrulo Pre - GuruFocus
Peering Into Halozyme Therapeutics's Recent Short Interest - Benzinga
Argenx stock rises on FDA nod for Vyvgart Hytrulo (ARGX) - Seeking Alpha
Halozyme Therapeutics Reports FDA Approval for Self-Injectable Syringe Developed in Partnership With Argenx - marketscreener.com
Halozyme :FDA Oks Argenx' VYVGART Hytrulo Prefilled Syringe For Generalized Myasthenia Gravis & CIDP - Nasdaq
Halozyme Announces FDA Approval of argenx's VYVGART® Hytrulo Prefilled Syringe Co-Formulated with ENHANZE® for Self-Injection for Generalized Myasthenia Gravis and Chronic Inflammatory Demyelinating Polyneuropathy - Citizen Tribune
J&J, Halozyme win EU nod for injectable Rybrevant in lung cancer - MSN
argenx Announces FDA Approval of VYVGART Hytrulo Prefilled Syringe for Self-Injection in Generalized Myasthenia Gravis and Chronic Inflammatory Demyelinating Polyneuropathy - GlobeNewswire Inc.
Game-Changing FDA Approval: New Self-Injectable Treatment Transforms Rare Disease Care - Stock Titan
Halozyme Therapeutics (HALO) Gains EU Approval for Injectable Co - GuruFocus
J&J, Halozyme get EU nod for Darzalex SC to treat multiple myeloma - Seeking Alpha
European Commission Approved Subcutaneous Darzalex (Daratumumab) Based Quadruplet Regimen - marketscreener.com
Halozyme Reports EC Approval For Indication Extension Of DARZALEX Co-formulated With ENHANZE - Nasdaq
European Commission Approved Subcutaneous DARZALEX® (daratumumab)-based Quadruplet Regimen for the Treatment of Patients with Newly Diagnosed Multiple Myeloma, Regardless of Transplant Eligibility - Quantisnow
Halozyme Therapeutics : Announces Roche Receives FDA Approval For Phesgo™ (Fixed-Dose Combination Of Perjeta® And Herceptin® For Subcutaneous Injection) Utilizing 's ENHANZE® Technology For The Treatment Of Patients With HER2-Positive Bre - MarketScreener
Halozyme Therapeutics : To Receive $10 Million Milestone Payment From Janssen - MarketScreener
Halozyme (HALO) Secures European Approval for J&J Antitumor Inje - GuruFocus
EC approves new lung cancer treatment using Halozyme technology By Investing.com - Investing.com South Africa
European Commission Approves Subcutaneous RYBREVANT® (amivantamab) Co-Formulated with ENHANZE® for the Treatment of Patients with Advanced EGFR-Mutated Non-Small Cell Lung Cancer - The Malaysian Reserve
Halozyme Says EC Approved Subcutaneous Rybrevant For Advanced EGFR-Mutated NSCLC - Nasdaq
EC approves new lung cancer treatment using Halozyme technology - Investing.com
European Commission Approves Subcutaneous Rybrevant® (Amivantamab) - MarketScreener
KLP Kapitalforvaltning AS Makes New Investment in Halozyme Therapeutics, Inc. (NASDAQ:HALO) - MarketBeat
Halozyme Therapeutics director Jeffrey Henderson sells $32,217 in stock - Investing.com Australia
Halozyme Therapeutics director Jeffrey Henderson sells $32,217 in stock By Investing.com - Investing.com South Africa
4,812 Shares in Halozyme Therapeutics, Inc. (NASDAQ:HALO) Purchased by EntryPoint Capital LLC - MarketBeat
Corebridge Financial Inc. Has $9.81 Million Holdings in Halozyme Therapeutics, Inc. (NASDAQ:HALO) - MarketBeat
Long Term Trading Analysis for (HALO) - news.stocktradersdaily.com
Halozyme: Bristol Myers Squibb Secures CHMP's Positive Opinion For New Cancer Drug Delivery Method - Nasdaq
Halozyme Announces Bristol Myers Squibb Received Positive CHMP Opinion for the Subcutaneous Formulation of Opdivo® (nivolumab) with ENHANZE® Across Multiple Solid Tumor Indications - Quantisnow
Major Breakthrough: New Cancer Drug Delivery Method Gets EU Panel Support - Stock Titan
Why Is Acadia (ACAD) Down 11.1% Since Last Earnings Report? - Yahoo Finance
Merck plans to launch US subcutaneous version of Keytruda on October 1 - Reuters
Halozyme Therapeutics (HALO) Stock Price, News & Analysis - MarketBeat
Myriad (MYGN) Down 17.1% Since Last Earnings Report: Can It Rebound? - Yahoo Finance
Halozyme stock soars to all-time high of $65.54 By Investing.com - Investing.com South Africa
Halozyme stock soars to all-time high of $65.54 - Investing.com India
Are You a Momentum Investor? This 1 Stock Could Be the Perfect Pick - Yahoo Finance
Halozyme Announces Retirement of Chief Technical Officer - TipRanks
Halozyme announces CTO retirement, effective immediately - Investing.com India
Halozyme announces CTO retirement, effective immediately By Investing.com - Investing.com Australia
Drug developers show mixed performance in early 2025 - BioWorld MedTech
Halozyme Therapeutics (HALO) is a Top-Ranked Value Stock: Should You Buy? - Yahoo Finance
Halozyme Joins the $1 Billion Club - Yahoo Finance
AstraZeneca signs $1.35B Alteogen deal for subcutaneous cancer drugs - Fierce Pharma
Halozyme Therapeutics: Steady Growth In A Challenged Market (NASDAQ:HALO) - Seeking Alpha
Halozyme Therapeutics Inc Azioni (HALO) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.15%
4.32%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):